search
     
     
     




    Karl-Ludwig Kley Receives Weizmann Award in the Sciences and Humanities

    February 16, 2016 – Merck,conferred the renowned Weizmann Award in the Sciences and Humanities on Karl-Ludwig Kley, CEO and Chairman of the Executive Board of Merck. “It is particularly important to us to acknowledge and honor your support and friendship with Israel and with the Weizmann Institute of Science,” Daniel Zajfman, President of the Weizmann Institute, said when conferring the Weizmann Award in the Sciences and Humanities to Kley Monday evening. “Throughout your career, you have expressed support and encouragement for Israel science and scientists; have been an exceptional friend to the Weizmann Institute; and have spearheaded and advanced the technology transfer relationship between the Institute and Merck with the goal of improving the lives of many people through better medical therapies.” “Over the past 10 years, my affection, empathy and friendship have grown with Israel and with the Weizmann Institute. I know that I am not only receiving an award from partners, but fr

    Merck and Weizmann Institute Sign New Framework Agreement on Research Collaboration

    February 16, 2016 – Merck,extended the partnership with Weizmann Institute of Science, Rehovot, Israel, of by signing a new framework agreement, building on a successful innovation partnership of almost four decades. Innovation was key for Merck’s now nearly 350 years of history and will play the same crucial role in the company’s future. The new framework agreement on research collaboration and licensing was signed by Stefan Oschmann, Deputy CEO and Vice Chairman of the Executive Board of Merck, Belén Garijo, Member of the Executive Board of Merck and CEO Healthcare, Prof. Mudi Sheves, Vice President of Technology Transfer of the Weizmann Institute, and Amir Naiberg, CEO of Yeda, the commercial arm of the Weizmann Institute, at Weizmann’s site in Rehovot, Israel, last night. It will span the next three years, with an option for multiple successive extensions of two years each. “We have focused our healthcare research activities on the highly promising fields of immuno-oncology, immu

    Merck Acquire Israeli Quantum Materials Company Qlight Nanotech

    New! Formulation Product Finder Application Tool